Advertisement
RayBiotech
RayBiotech

Glimpses of stem cell medicine

After three days of discussions about stem cell machinery, the organizers concluded the linkurl:Keystone meeting;http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=786 on stem cell biology today by treating participants to data showing what these cells can already do in humans. These efforts appear not quite as differentiated as stem cells themselves, but are hopefully on their way to becoming so. Tonight, Michele De Luca from the Veneto Eye Bank Foundation and the University o

By | April 1, 2006

After three days of discussions about stem cell machinery, the organizers concluded the linkurl:Keystone meeting;http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=786 on stem cell biology today by treating participants to data showing what these cells can already do in humans. These efforts appear not quite as differentiated as stem cells themselves, but are hopefully on their way to becoming so. Tonight, Michele De Luca from the Veneto Eye Bank Foundation and the University of Modena in Italy presented a series of stomach-churning videos and images illustrating how he and his colleagues used autologous stem cells to correct both blindness and a rare, blistering skin disease. In a study involving nearly 200 people blinded after burns depleted their stores of limbal stem cells, stem cell transplants corrected the vision of the majority of patients, even several years after the operation. Another man with epidermolysis bullosa (EB), a disease in which the slightest trauma causes major damage to the skin, received transplants of his own genetically corrected epidermal stem cells, and experienced major improvements in the areas that received the transplant. Four months after the procedure, "there is a complete regeneration of the epidermis," De Luca told the audience. (Indeed, the pictures showed remarkable differences between the swaths of treated and untreated skin.) De Luca said he plans to continue the experiment, transplanting the rest of the patient?s skin "step by step." Following De Luca?s presentation, linkurl:Ronald McKay;http://intra.ninds.nih.gov/Lab.asp?Org_ID=25 from the National Institutes of Health estimated that as early as within the next several months, researchers might obtain dopamine neurons from human embryonic stem cells -- a potentially major advance for people diagnosed with Parkinson?s disease. However, he and his co-presenter, linkurl:Olle Lindvall;http://www.medfak.lu.se/stemcellcenter/olle_lindvall.htm from the Wallenberg Neuroscience Center in Lund, Sweden, cautioned against immediate enthusiasm. Lindvall noted that one first has to demonstrate that these new cells work, and work better than existing therapies, to justify testing them in humans. McKay agreed, noting that, despite the immediate need, it?s vital to first understand the developmental biology of the system before proceeding to the clinic. We even saw promising data from studies of man?s best friend, the dog -- in this case, golden retrievers with a form of muscular dystrophy. Curiously, the experiments, conducted by Giulio Cossu from the University La Sapienza in Italy, and his colleagues, showed that transplants of wild type donor stem cells appeared to work better than autologous, corrected stem cell transplants -- a finding deemed "amazing" by an audience member during the Question & Answer period following the presentation.
Advertisement

Comments

Avatar of: StemCellSummit

StemCellSummit

Posts: 1

October 5, 2006

Want the latest on stem cells, please visit www.stemcellsummit.com\n\nThe commercialization of stem cell and progenitor cell therapies has begun. This year, there are estimates that revenues generated from the sales of stem cells in humans will exceed $15 million and are on track to double in the coming year. \n\nThe number of patients treated for fracture repair or bone growth are estimated to exceed 4,000.\n\nIn the coming 24 months, one and possibly more new stem cell therapies will come to market for treatments of cancer patients, auto-immune disorders or cartilage repair.\n\nSoon after that, cellular therapies to treat cardiovascular maladies will be available.\n\nThese coming three years are the golden years when the value and potential of stem cell therapies will burst onto the medical scene. These are also the years when investors, surgeons, and business development executives for medical technology can lay the foundations for future investments.\n\nHow will this revolution affect medicine? \n\nWe quote from Dr. James Thomson, the stem cell pioneer from the University of Wisconsin; ?I think (the stem-cell) field will parallel gene therapy quite closely. If you go back to the early days of recombinant DNA or gene manipulation, in the early 1970?s, there was a very similar kind of social uproar to what happened with human embryonic stem cells. It was followed ultimately by compromise and the work getting done. Nonetheless, recombinant DNA has completely revolutionized how biology is done in this country and the rest of the world. Stem cell therapies, I have complete confidence, are going to change human medicine.? \n\nFor the first time ever, a stem cell seminar is being organized to emphasize the commercial aspects of Stem Cell Therapies. Never before have clinicians and scientists been in one place, at one time, to deliver the REAL STEM CELL STORY. The presenters will include the leading companies in this field, clinicians and scientists.\n\nFurthermore, we will be featuring the first LIVE stem cell therapy broadcast. \n\nPlease visit www.stemcellsummit.com\n\n\n

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
The Scientist
The Scientist